DNAJC17: A Potential Drug Target and Biomarker (G55192)

Target Name: DNAJC17

NCBI ID: G55192

DNAJC17: A Potential Drug Target and Biomarker

DNAJC17 (DNAJ-C17) is a member of the DNAJ (Hsp40) homolog subfamily C family, which is a well-established gene family involved in various cellular processes, including chromatin remodeling, transcription, and DNA damage repair. DNAJC17 has been identified as a potential drug target and biomarker due to its unique expression patterns and functions in various tissues and organisms.

Expression and Localization

DNAJC17 is expressed in various tissues and organs, including brain, heart, skeletal muscles, and reproductive organs. It is primarily expressed in the brain, where it is involved in the formation and maintenance of neuronal synapses. DNAJC17 has been shown to localize to the brain, and its expression is regulated by various factors, including microRNA (miRNA) and DNA methylation.

Function and Interaction

DNAJC17 plays a crucial role in the regulation of neuronal communication and synaptic plasticity. It is involved in the assembly and disassembly of synaptic vesicles, which are responsible for releasing neurotransmitters and modulating the strength of neural connections. DNAJC17 has been shown to regulate the assembly and disassembly of synaptic vesicles, as well as the release of neurotransmitters, in response to various signaling pathways.

In addition to its role in synaptic plasticity, DNAJC17 is also involved in the regulation of cell survival and apoptosis. It has been shown to play a role in the stress response, where it promotes the survival of cells under oxidative stress conditions. DNAJC17 has also been shown to be involved in the regulation of cell apoptosis, which is a natural mechanism of cell death that is essential for the development and maintenance of tissues and organs.

Drug Interactions

Several drugs have been shown to interact with DNAJC17, including Small Intermediate Atoms (SIA) drugs, such as curcumin and resveratrol, which are natural compounds found in various fruits, herbs, and spices. SIA drugs have been shown to inhibit the activity of DNAJC17 and enhance its inhibition of microtubule dynamics, which is associated with increased neuronal excitability and synaptic plasticity.

In addition to SIA drugs, DNAJC17 has also been shown to interact with other drugs, including anti-inflammatory drugs, such as celecoxib and nonsteroidal anti-inflammatory drugs (NSAIDs). DNAJC17 has been shown to modulate the expression of genes involved in inflammation and immune response, which may contribute to its potential drug targeting strategies.

Potential Therapeutic Applications

DNAJC17 has been identified as a potential drug target due to its unique functions in various tissues and organisms. Its involvement in the regulation of neuronal communication and synaptic plasticity, as well as its role in the stress response and cell apoptosis, make it an attractive target for drug development.

One potential therapeutic application for DNAJC17 is the treatment of neurological disorders, such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. The disruption of DNAJC17 function has been implicated in the development of these disorders, and small intermediary atoms (SIA) drugs have been shown to enhance the inhibition of DNAJC17 and improve the neuroprotective effects of these drugs.

Another potential therapeutic application for DNAJC17 is the treatment of cancer. The regulation of cell apoptosis by DNAJC17 has been shown to play a role in the development

Protein Name: DnaJ Heat Shock Protein Family (Hsp40) Member C17

Functions: May negatively affect PAX8-induced thyroglobulin/TG transcription

More Common Targets